Granted Patent
B2
US 12,336,999 · App. 18/526,225 · Granted Jun 24, 2025
Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl) pyrazolo[3,4-d] pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl) piperazin-1-yl]pent-2-enenitrile
Inventors:
Abu J. Ferdous (Belmont, CA); Mohammad R. Masjedizadeh (San Jose, CA); Wu Lin (Nottingham, GB)
Assignee:
Principia Biopharma Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Modified release formulations, such as solid oral dosage forms comprising a core composition comprising Compound (I) and/or a pharmaceutically acceptable salt thereof; a sub-coating layer coating the core composition, said sub-coating layer comprising a polyvinyl alcohol and/or a hydroxypropyl methyl cellulose; and an enteric coating layer encapsulating the sub-coating layer and the core composition, said enteric coating layer comprising at least one polymer selected from an acrylic/methacrylic/ethacrylic acid homopolymer and copolymers thereof, a cellulose derivative, and a polyvinylpyrrolidone, and methods of administration of a Bruton's tyrosine kinase (BTK) inhibitor using said formulations.
Claims (43)
1. A method of inhibiting Bruton's tyrosine kinase (BTK) in a mammal in need thereof comprising administering to the mammal in need of such BTK inhibition a therapeutically effective amount of a modified release solid oral dosage form comprising:
(a) a core composition comprising a (E) isomer, a (Z) isomer, a mixture of (E) and (Z) isomers of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl) pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile, (S)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl) pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile, or a mixture of (R) and(S) isomers of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl) pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (Compound I) having the structure:
where *C is a stereochemical center, or a pharmaceutically acceptable salt thereof; wherein the core composition comprises by weight:
about 6% to about 20% of Compound (I) or a pharmaceutically acceptable salt thereof;
about 34% to about 72% of microcrystalline cellulose;
about 5% to about 25% mannitol;
about 0% to about 20% of hydroxypropyl methyl cellulose;
about 0.5% to about 1.5% of crosslinked homopolymer of N-vinyl-2-pyrrolidone; and
about 0.5% to about 1.5% of sodium stearyl fumarate;
(b) a sub-coating layer coating the core composition, the sub-coating layer comprising a polyvinyl alcohol and/or a hydroxypropyl methyl cellulose; and
(c) an enteric coating layer encapsulating the sub-coating layer and the core composition, the enteric coating layer comprising at least one polymer selected from an acrylic/methacrylic/ethacrylic acid homopolymer and copolymers thereof, a cellulose derivative, and a polyvinylpyrrolidone.
2. A method of treating a disease mediated by Bruton's tyrosine kinase (BTK) in a mammal in need thereof comprising administering to the mammal in need of such disease treatment a therapeutically effective amount of a modified release solid oral dosage form comprising:
(a) a core composition comprising a (E) isomer, a (Z) isomer, a mixture of (E) and (Z) isomers of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl) pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile, (S)-2-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl) pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile, or a mixture of (R) and(S) isomers of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl) pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (Compound I) having the structure:
where *C is a stereochemical center, or a pharmaceutically acceptable salt thereof; wherein the core composition comprises by weight:
about 6% to about 20% of Compound (I) or a pharmaceutically acceptable salt thereof;
about 34% to about 72% of microcrystalline cellulose;
about 5% to about 25% mannitol;
about 0% to about 20% of hydroxypropyl methyl cellulose;
about 0.5% to about 1.5% of crosslinked homopolymer of N-vinyl-2-pyrrolidone; and
about 0.5% to about 1.5% of sodium stearyl fumarate;
(b) a sub-coating layer coating the core composition, the sub-coating layer comprising a polyvinyl alcohol and/or a hydroxypropyl methyl cellulose; and
(c) an enteric coating layer encapsulating the sub-coating layer and the core composition, the enteric coating layer comprising at least one polymer selected from an acrylic/methacrylic/ethacrylic acid homopolymer and copolymers thereof, a cellulose derivative, and a polyvinylpyrrolidone.
3. The method of claim 2 , wherein the disease is an autoimmune disease, an inflammatory disease, or cancer.
4. The method of claim 2 , wherein the disease is selected from at least one of acute necrotizing hemorrhagic leukoencephalitis, acute disseminated encephalomyelitis, autoimmune inner ear disease (AIED), autoimmune retinopathy, axonal & neuronal neuropathies, chronic inflammatory demyelinating polyneuropathy (CIDP), demyelinating neuropathies, Devic's disease (neuromyelitis optica), experimental allergic encephalomyelitis, giant cell arteritis (temporal arteritis), Guillain-Barre syndrome, Lambert-Eaton syndrome, chronic Meniere's disease, myasthenia gravis, neuromyotonia, opsoclonus-myoclonus syndrome, optic neuritis, paraneoplastic cerebellar degeneration, peripheral neuropathy, perivenous encephalomyelitis, restless legs syndrome, stiff person syndrome, sympathetic ophthalmia, Takayasu's arteritis, temporal arteritis/Giant cell arteritis, transverse myelitis, multiple sclerosis, dysautonomia, age-related macular degeneration (wet and dry), corneal transplantation, encephalitis, meningitis, vasculitis, and systemic lupus erythematosus (SLE).
5. The method of claim 2 , wherein the disease is selected from at least one of rheumatoid arthritis, psoriatic arthritis, lupus, uveitis, myasthenia gravis, warm autoimmune hemolytic anemia, Wegener's granulomatosis, Sjogren's disease, Sjogren's dry eye, non-Sjogren's dry eye disease, psoriasis, pemphigus, urticaria, and asthma.
6. The method of claim 2 , wherein the disease is selected from at least one of diffuse large B cell lymphoma, follicular lymphoma, chronic lymphocytic lymphoma, chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, small lymphocytic lymphoma (SLL), multiple myeloma, B-cell non-Hodgkin lymphoma, lymphoplamascytic lymphoma/Waldenstrom macroglobulinemia, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, mantle cell lymphoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, Burkitt lymphoma/leukemia, and lymphomatoid granulomatosis.
7. The method of claim 2 , wherein the Compound (I) and/or the pharmaceutically acceptable salt thereof is administered in combination with one or more anti-cancer or anti-inflammatory agents.
8. The method of claim 2 , wherein the disease is selected from at least one of IgG4-related sclerosing disease, dermatitis, atopic dermatitis, contact dermatitis, idiopathic thrombocytopenia purpura (ITP), autoimmune thrombocytopenia purpura (ATP), thrombocytopenia purpura (TTP), and secondary thrombocytopenia.
9. The method of claim 2 , wherein the cellulose derivative is selected from cellulose acetate phthalate, cellulose acetate tritnellitate, methylcellulose, hydroxypropylmethyl cellulose phthalate (HPMCP), hydroxypropylmethyl cellulose succinate (HPMCS), and hydroxypropylmethylcellulose acetate succinate (HPMCAS).
10. The method of claim 2 , wherein the sub-coating layer (b) comprises a polyvinyl alcohol, and the enteric coating layer (c) comprises a poly (methacrylic acid-co-ethyl acrylate) copolymer.
11. The method of claim 2 , wherein:
the modified release solid oral dosage form releases less than about 10% by weight of Compound (I) or a pharmaceutically acceptable salt thereof in less than two hours at a pH less than or equal to about 2.0;
at least about 80% by weight of Compound (I) or a pharmaceutically acceptable salt thereof in about 15 minutes to about two hours at a pH equal to or more than about 6.0; and
any unreleased amount of Compound (I) is released by the end of about 7.5 hours at a pH equal to or more than about 6.0.
12. The method of claim 2 , wherein the core composition comprises Compound (I).
13. The method of claim 2 , wherein Compound (I) or a pharmaceutically acceptable salt thereof is an (E) and (Z) mixture of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-pyrazolo [3,4-d] pyrimidin-1-yl] piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl) piperazin-1-yl] pent-2-enenitrile.
14. The method of claim 2 , wherein at least about 85% by weight of Compound (I) or a pharmaceutically acceptable salt thereof is the (E) isomer.
15. The method of claim 2 , wherein at least about 90% by weight of Compound (I) or a pharmaceutically acceptable salt thereof is the (E) isomer.
16. The method of claim 2 , wherein Compound (I) or a pharmaceutically acceptable salt thereof is a substantially pure amorphous form.
17. The method of claim 2 , wherein the core composition comprises about 30 mg to about 100 mg of Compound (I) or a pharmaceutically acceptable salt thereof.
18. The method of claim 2 , wherein the sub-coating layer weighs about 2% to about 4% by weight of the modified release solid oral dosage form.
19. The method of claim 2 , wherein the enteric coating layer weighs about 6% to about 20% of the total weight of the modified release solid oral dosage form.
20. The method of claim 2 , wherein the core composition weighs about 80% to about 91% of the total weight of the modified release solid oral dosage form.
Assignments (4)
ASSIGNEE CHANGE OF ADDRESS
Recorded Sep 16, 2025
From: PRINCIPIA BIOPHARMA INC.
To: PRINCIPIA BIOPHARMA INC.
Reel/Frame 072881/0270 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 11, 2024
From: LIN, WU
To: QUOTIENT CLINICAL LIMITED
Reel/Frame 066098/0870 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 11, 2024
From: MASJEDIZADEH, MOHAMMAD; FERDOUS, ABU
To: PRINCIPIA BIOPHARMA INC.
Reel/Frame 066098/0927 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 11, 2024
From: QUOTIENT CLINICAL LIMITED
To: PRINCIPIA BIOPHARMA INC.
Reel/Frame 066098/0981 →
Continuity (4)
Continuation
16312258
Provisional Application
62356345
· Jun 29, 2016
References Cited (400)
US 4721710A
· Bernhart et al.
· 1988
[cited by applicant]
US 4861760A
· Mazuel et al.
· 1989
[cited by applicant]
US 4911920A
· Jani et al.
· 1990
[cited by applicant]
US 5212162A
· Missel et al.
· 1993
[cited by applicant]
US 5403841A
· Lang et al.
· 1995
[cited by applicant]
US 5514711A
· Kitano et al.
· 1996
[cited by applicant]
US 5792771A
· App et al.
· 1998
[cited by applicant]
US 6331555B1
· Hirth et al.
· 2001
[cited by applicant]
US 6410486B2
· Wetterich et al.
· 2002
[cited by applicant]
US 6596746B1
· Das et al.
· 2003
[cited by applicant]
US 6660744B1
· Hirst et al.
· 2003
[cited by applicant]
US 7217682B2
· Mori
· 2007
[cited by applicant]
US 7514444B2
· Honigberg et al.
· 2009
[cited by applicant]
US 7700648B2
· Mori
· 2010
[cited by applicant]
US 8673925B1
· Goldstein
· 2014
[cited by applicant]
US 8759358B1
· Goldstein
· 2014
[cited by applicant]
US 8828426B2
· Shah et al.
· 2014
[cited by applicant]
US 8940744B2
· Owens et al.
· 2015
[cited by applicant]
US 8946241B2
· Goldstein
· 2015
[cited by applicant]
US 8957080B2
· Goldstein et al.
· 2015
[cited by applicant]
US 8962635B2
· Goldstein
· 2015
[cited by applicant]
US 8962831B2
· Goldstein
· 2015
[cited by applicant]
US 9090621B2
· Goldstein
· 2015
[cited by applicant]
US 9266895B2
· Owens et al.
· 2016
[cited by applicant]
US 9376438B2
· Goldstein et al.
· 2016
[cited by applicant]
US 9572811B2
· Babler et al.
· 2017
[cited by applicant]
US 9688676B2
· Owens
· 2017
[cited by applicant]
US 9994576B2
· Owens et al.
· 2018
[cited by applicant]
US 20030153752A1
· Hirst et al.
· 2003
[cited by applicant]
US 20050008640A1
· Waegell et al.
· 2005
[cited by applicant]
US 20050065176A1
· Field et al.
· 2005
[cited by applicant]
US 20060025383A1
· Wishart et al.
· 2006
[cited by applicant]
US 20060058324A1
· Capraro et al.
· 2006
[cited by applicant]
US 20060079494A1
· Santi et al.
· 2006
[cited by applicant]
US 20060275376A1
· Guimberteau et al.
· 2006
[cited by applicant]
US 20070149464A1
· Billen et al.
· 2007
[cited by applicant]
US 20080146643A1
· Billen et al.
· 2008
[cited by applicant]
US 20080176865A1
· Billen et al.
· 2008
[cited by applicant]
US 20080260818A1
· Penhasi et al.
· 2008
[cited by applicant]
US 20100113520A1
· Miller
· 2010
[cited by applicant]
US 20100280035A1
· Becker et al.
· 2010
[cited by applicant]
US 20120028981A1
· Miller
· 2012
[cited by applicant]
US 20120071497A1
· Buggy et al.
· 2012
[cited by applicant]
US 20130197014A1
· Chen et al.
· 2013
[cited by applicant]
US 20140142099A1
· Owens
· 2014
[cited by applicant]
US 20150140085A1
· Goldstein
· 2015
[cited by applicant]
US 20150209432A1
· Konda et al.
· 2015
[cited by applicant]
US 20150328310A1
· Allen et al.
· 2015
[cited by applicant]
US 20150353557A1
· Goldstein et al.
· 2015
[cited by applicant]
US 20150353562A1
· Goldstein
· 2015
[cited by applicant]
US 20160045503A1
· Goldstein et al.
· 2016
[cited by applicant]
US 20160113913A1
· Murakawa et al.
· 2016
[cited by applicant]
US 20160257686A1
· Owens
· 2016
[cited by applicant]
US 20180015088A1
· Nunn et al.
· 2018
[cited by applicant]
US 20180162861A1
· Goldstein et al.
· 2018
[cited by applicant]
US 20180193274A1
· Nunn et al.
· 2018
[cited by applicant]
US 20180305350A1
· Goldstein et al.
· 2018
[cited by applicant]
US 20190231784A1
· Ferdous et al.
· 2019
[cited by applicant]
US 20210106584A1
· Gourlay et al.
· 2021
[cited by applicant]
CA 2890111A1
· 2014
[cited by applicant]
CN 1274280A
· 2000
[cited by applicant]
CN 1681483A
· 2005
[cited by applicant]
CN 1874761A
· 2006
[cited by applicant]
CN 101287452A
· 2008
[cited by applicant]
CN 101610676A
· 2009
[cited by applicant]
CN 101730699A
· 2010
[cited by applicant]
CN 101880243A
· 2010
[cited by applicant]
CN 102159214A
· 2011
[cited by applicant]
CN 101610676B
· 2013
[cited by applicant]
CN 103096716A
· 2013
[cited by applicant]
CN 101805341A
· 2013
[cited by applicant]
CN 101805341B
· 2013
[cited by applicant]
CN 103534258A
· 2014
[cited by applicant]
CN 104640861A
· 2015
[cited by applicant]
CN 104736178A
· 2015
[cited by applicant]
CN 104822681A
· 2015
[cited by applicant]
CN 103096716B
· 2016
[cited by applicant]
CN 105753863A
· 2016
[cited by applicant]
CN 103534258B
· 2016
[cited by applicant]
CN 106456652A
· 2017
[cited by applicant]
CN 110483521A
· 2019
[cited by applicant]
CN 106456652B
· 2020
[cited by applicant]
EP 0461546A2
· 1991
[cited by applicant]
EP 0493767A2
· 1992
[cited by applicant]
EP 0461546A3
· 1993
[cited by applicant]
EP 0493767A3
· 1993
[cited by applicant]
EP 0908457A1
· 1999
[cited by applicant]
EP 2443929A1
· 2012
[cited by applicant]
EP 2578585A1
· 2013
[cited by applicant]
EP 2578585B1
· 2016
[cited by applicant]
FR 2535721A1
· 1984
[cited by applicant]
GB 2447933A
· 2008
[cited by applicant]
JP 5663950A
· 1981
[cited by applicant]
JP 021450
· 1990
[cited by applicant]
JP 04177244
· 1992
[cited by applicant]
JP 2005239657A
· 2005
[cited by applicant]
JP 2010504324A
· 2010
[cited by applicant]
JP 2010235628A
· 2010
[cited by applicant]
JP 2014513729A
· 2014
[cited by applicant]
JP 2014517838A
· 2014
[cited by applicant]
JP 2015522653A
· 2015
[cited by applicant]
JP 2016503063A
· 2016
[cited by applicant]
JP 6203848B2
· 2017
[cited by applicant]
WO 9524190A2
· 1995
[cited by applicant]
WO 9531432A1
· 1995
[cited by applicant]
WO 9841499A1
· 1998
[cited by applicant]
WO 9914216A1
· 1999
[cited by applicant]
WO 9918938A1
· 1999
[cited by applicant]
WO 0172751A1
· 2001
[cited by applicant]
WO 02066463A1
· 2002
[cited by applicant]
WO 03037890A2
· 2003
[cited by applicant]
WO 03050080A1
· 2003
[cited by applicant]
WO 03068157A2
· 2003
[cited by applicant]
WO 03082807A2
· 2003
[cited by applicant]
WO 2004016259A1
· 2004
[cited by applicant]
WO 2004074283A1
· 2004
[cited by applicant]
WO 2005020929A2
· 2005
[cited by applicant]
WO 2005023773A1
· 2005
[cited by applicant]
WO 2005030184A2
· 2005
[cited by applicant]
WO 2005085210A1
· 2005
[cited by applicant]
WO 2006086634A2
· 2006
[cited by applicant]
WO 2006134468A1
· 2006
[cited by applicant]
WO 2007043401A1
· 2007
[cited by applicant]
WO 2007087068A2
· 2007
[cited by applicant]
WO 2007130075A1
· 2007
[cited by applicant]
WO 2007142755A2
· 2007
[cited by applicant]
WO 2008005954A2
· 2008
[cited by applicant]
WO 2008006032A1
· 2008
[cited by applicant]
WO 2007087068A3
· 2008
[cited by applicant]
WO 2008039218A2
· 2008
[cited by applicant]
WO 2008054827A2
· 2008
[cited by applicant]
WO 2008061740A1
· 2008
[cited by applicant]
WO 2008072053A2
· 2008
[cited by applicant]
WO 2008072077A2
· 2008
[cited by applicant]
WO 2008116064A2
· 2008
[cited by applicant]
WO 2008121742A2
· 2008
[cited by applicant]
WO 2009140128A2
· 2009
[cited by applicant]
WO 2009143477A1
· 2009
[cited by applicant]
WO 2010009342A2
· 2010
[cited by applicant]
WO 2010014930A2
· 2010
[cited by applicant]
WO 2010065898A2
· 2010
[cited by applicant]
WO 2011031896A2
· 2011
[cited by applicant]
WO 2011046964A2
· 2011
[cited by applicant]
WO 2011060440A2
· 2011
[cited by applicant]
WO 2011144585A1
· 2011
[cited by applicant]
WO 2011152351A1
· 2011
[cited by applicant]
WO 2011153514A2
· 2011
[cited by applicant]
WO 2012021444A1
· 2012
[cited by applicant]
WO 2012158764A1
· 2012
[cited by applicant]
WO 2012158795A1
· 2012
[cited by applicant]
WO 2012158810A1
· 2012
[cited by applicant]
WO 2012158843A2
· 2012
[cited by applicant]
WO 2013003629A2
· 2013
[cited by applicant]
WO 2013010136A2
· 2013
[cited by applicant]
WO 2013010380A1
· 2013
[cited by applicant]
WO 2013010868A1
· 2013
[cited by applicant]
WO 2013010869A1
· 2013
[cited by applicant]
WO 2013041605A1
· 2013
[cited by applicant]
WO 2013059738A2
· 2013
[cited by applicant]
WO 2013102059A1
· 2013
[cited by applicant]
WO 2013116382A1
· 2013
[cited by applicant]
WO 2013184572A1
· 2013
[cited by applicant]
WO 2013185082A2
· 2013
[cited by applicant]
WO 2013191965A1
· 2013
[cited by applicant]
WO 2014004707A1
· 2014
[cited by applicant]
WO 2014022569A1
· 2014
[cited by applicant]
WO 2014039899A1
· 2014
[cited by applicant]
WO 2014068527A1
· 2014
[cited by applicant]
WO 2014078578A1
· 2014
[cited by applicant]
WO 2014164558A1
· 2014
[cited by applicant]
WO 2014171542A1
· 2014
[cited by applicant]
WO 2015127310A1
· 2015
[cited by applicant]
WO 2015132799A2
· 2015
[cited by applicant]
WO 2016100914A1
· 2016
[cited by applicant]
WO 2016105531A1
· 2016
[cited by applicant]
WO 2017041536A1
· 2017
[cited by applicant]
WO 2017066014A1
· 2017
[cited by applicant]
WO 2018005849A1
· 2018
[cited by applicant]
WO 2019208805A1
· 2019
[cited by applicant]
WO 2021076514A1
· 2021
[cited by applicant]
WO 2022081512A1
· 2022
[cited by applicant]
Structure-Based Search Results (May 9, 2011, 8:23 PM), SciFinder.
[cited by applicant]
Structure-Based Search Results (May 9, 2011, 8:33 PM), SciFinder.
[cited by applicant]
Structure-Based Search Results (May 9, 2011, 9:06 PM), SciFinder.
[cited by applicant]
Van Beek, N. et al., “Therapy of pemphigus”, Hautarzt, Springer Verlag, Berlin, DE, vol. 70, No. 4, pp. 243-253 (Mar. 18, 2019).
[cited by applicant]
Vayne, C., et al., “Pathophysiology and Diagnostic of Drug-Induced Immune Thrombocytopenia,” Journal of Clinical Medicine, vol. 9, No. 7, p. 2212 (2020).
[cited by applicant]
Verhe, R., et al., “Preparation of 2,2-Dialkylcyclopropanes Geminally Substituted with Electron-Withdrawing Groups,” Synthesis, vol. 7, pp. 530-532 (1978).
[cited by applicant]
Verhe, R., et al., “Synthesis of 1,1-Bis(Hydroxymethyl) Cyclopropanes,” Organic Preparations and Procedures International, vol. 13, No. 1, pp. 13-18 (1981).
[cited by applicant]
Verhe, R., et al., “Thermal Lactonization of Brominated Alkylidenemalonates: Synthesis of 2-Buten-4-Olides,” Bulletin des Societes Chimiques Belges, vol. 87, No. 3, pp. 215-222 (1978).
[cited by applicant]
Vo, N., et al., “Transformations of Resin-Bound Pyridinium Ylides: I. A Stereoselective Synthesis of 2,2,3-Trisubstituted Cyclopropanecarboxylates,” Tetrahedron Letters, vol. 38, No. 46, pp. 7951-7954 (1997).
[cited by applicant]
Von Hundelshausen, P., et al., “Vaccine-Induced Immune Thrombotic Thrombodytopenia (VITT): Targeting Pathomechanisms with Bruton Tyrosine Kinase Inhibitors”, Thrombosis and Haemostasis, vol. 121, No. 11, pp. 1395-1399 (…
[cited by applicant]
Wang, G., et al., “Substituted 4-amino-1H-pyrazolo[3,4-d]pyrimidines as multi-targeted inhibitors of insulin-like growth factor-I receptor (IGFIR) and members of ErbB-family receptor kinases,” Bioorganic Medicinal and C…
[cited by applicant]
Wang, K., et al., “Cyanoacetamide Multicomponent Reaction (I): Parallel Synthesis of Cyanoacetamides,” Journal of Combinatorial Chemistry, vol. 11, pp. 920-927 (2009).
[cited by applicant]
WebMD. 10 Ways to Prevent Psoriasis Flare-Ups. Web: (2016).
[cited by applicant]
WebMD. Multiple Sclerosis (MS)-Prevention. Web: < http://www.webmd.com/multiple-sclerosis/tc/multiple-sclerosis-ms-prevention> (2015).
[cited by applicant]
Wells, G., et al., “Structural Studies on Bioactive Compounds. 32.1 Oxidation of Tyrphostin Protein Tyrosine Kinase Inhibitors with Hypervalent Iodine Reagents,” Journal of Medicinal Chemistry, vol. 43. pp. 1550-1562 (2…
[cited by applicant]
WhatisDryEye.com. Dry Eye vs. Conjunctivitis Web: (2016).
[cited by applicant]
Wilding, I., et al., “Targeting of Drugs and Vaccines to the Gut,” Pharmacology and Therapeutics, vol. 62, pp. 97-124 (1994).
[cited by applicant]
Wissner, A., et al., “Synthesis and Structure-Activity Relationships of 6,7-Disubstituted 4-Anilinoquinoline-3-carbonitriles. The Design of an Orally Active, IrreversibleInhibitor of the Tyrosine Kinase Activity of the …
[cited by applicant]
Wong, J.D., “The ruthless player in purpura: immune thrombocytopenia purpura,” https://tpech.gov.taipei/mp109181/News_Content.aspx?n=80359412498D4193&sms =D6D8C221F7AECFEE&s=0419C614DFB65D7A, Sep. 4, 2012.
[cited by applicant]
Zhang, F., et al., “Organic base catalyzed carbonyl allylation of methyl trifluoropyruvate with activated alkenes,” Tetrahedron Letters, vol. 65, pp. 83-86 (2009).
[cited by applicant]
Zhensu, L., Medicinal Chemistry, Chemical Industry Press, China, Mar. 3, 1981, pp. 435-436.
[cited by applicant]
Zimmerman, H., et al., “The Diverted Di-TT-Methane Rearrangement; Mechanistic and Exploratory Organic Photochemistry,” Organic Letters, vol. 4, No. 7, pp. 1155-1158 (2002).
[cited by applicant]
U.S. Appl. No. 63/176,543, filed Apr. 19, 2021, Christopher W. Smith.
[cited by applicant]
“Solubility, Polymorphism, Crystallinity, and Crystal Habit of Acetaminophen and Ibuprofen by Initial Solvent Screening,” PharmaTech.com, vol. 30, No. 10, pp. 1-3 (2006).
[cited by applicant]
“Supplement Article”, The Authors, British Journal of Haematology, vol. 185, suppl. 1, pp. 3-202 (2019).
[cited by applicant]
2012 ICD-9-CM Diagnosis Code 372.30: Conjunctivitis, unspecified, retrieved Aug. 4, 2016 (1 page).
[cited by applicant]
Abdulahad, W., et al., “Immune regulation and B-cell depletion therapy in patients with primary Sjogren's syndrome,” J Autoimmun, 39(1): 103-111 (2012).
[cited by applicant]
Abstract for Neplyuev, V., “Nitration and nitrosation of 1, 1,3,3-tetraacyl-1-propenes” Ukrainskii Khimicheskii Zhurnal (Russian Edition), 49(2):192-194 (1 page) (1983).
[cited by applicant]
Abstract for Neplyuev, V., “Studies of triacylmethanes VII. 1, 1,3,3-Tetraacyl-3-arylazo-1-propenes,” Zhurnal Organicheskoi Khimii, 15(3): 563-566 (1 page) (1979).
[cited by applicant]
American Cancer Society. Can Non-Hodgkin's Lymphoma Be Prevented? (2016) Web: (3 pages).
[cited by applicant]
Ansel, H., et al., “Pharmaceutical Dosage Forms and Drug Delivery Systems,” Seventh Edition, Lippincott Williams & Wilkins, A Wolters Kluwer Company, Chapters 1-8, pp. 1-243 (1999).
[cited by applicant]
Armesto, D., et al., “Efficient photochemical synthesis of 2-vinylcyclopropanecarbaldehydes, precursors of cyclopropane components present i1 pyrethroids, by using the oxa-di-TT-methane rearrangement,” Tetrahedron, 66: …
[cited by applicant]
Arnold, L., et al., “Pyrrolo[2,3-d]pyrimidines Containing an Extended 5-Substituent as Potent and Selective Inhibitors of Ick I,” Bioorg. Med. Chem. Lett., 10:2167-2170 (2000).
[cited by applicant]
Arora, A., et al., “Role of Tyrosine Kinase Inhibitors in Cancer Therapy,” J Pharmacol. Exp. Ther., 315(3):971-979 (2005).
[cited by applicant]
Audia, S., et al., “Pathogenesis of immune thrombocytopenia,” Autoimmunity Reviews, vol. 16, pp. 620-632, Apr. 17, 2017.
[cited by applicant]
Basheer, A., et al., “Enols of Substituted Cyanomalonamides,” J Org. Chem. 72:5297-5312 (2007).
[cited by applicant]
Bastin, R., et al., “Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities,” Org. Process Res. Dev, 4:427-435 (2000).
[cited by applicant]
Berge, S., et al., “Pharmaceutical Salts,” J Pharm. Sci., 66:1-19 (1977).
[cited by applicant]
Bernhart, C., et al., “Synthesis and Antiarrhythmic activity of New [(Dialkylamino)alkyl]pyridylacetamides,” J Med Chem., 26:451-455 (1983).
[cited by applicant]
Bobkova, I., et al., “Modern view on the treatment of membranous nephropathy,” Therapeutic archive, vol. 6, pp. 99-104 (2020).
[cited by applicant]
Burchat, A., et al., “Pyrrolo[2,3-d]pyrimidines Containing an Extended 5-Substituent as Potent and Selective Inhibitors of Ick II,” Bioorg. Med. Chem. Lett, 10:2171-2174 (2000).
[cited by applicant]
Burini, E., et al., “Efficient Synthesis of 4-Cyano 2,3-Dihydrooxazoles by Direct Amination of 2-Alkylidene 3-Oxo Nitriles,” Synlett, 17: 2673-2675 (2005).
[cited by applicant]
Bussel, J., et al., “A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia,” Blood, vol. 118, No. 1, pp. 28-36 (2011).
[cited by applicant]
Caira, M., et al., “Crystalline Polymorphism of Organic Compounds,” Topics in Current Chemistry, vol. 198, pp. 163-208 (1998).
[cited by applicant]
Calderwood, D., et al., “Pyrrolo[2,3-d]pyrimidines Containing Diverse N-7 Substituents as Potent Inhibitors of Lck,” Bioorg. Med. Chem. Lett., 12:1683-1686 (2002).
[cited by applicant]
Carruthers, M., et al., “Development of an IgG4-RD Responder Index,” International Journal of Rheumatology, vol. 2012, pp. 1-8 (2012).
[cited by applicant]
CAS RN 26272-41-3, STN entered Nov. 16, 1984 (1 page).
[cited by applicant]
Certified English Translation of CN 105753863 A published in Chinese on Jul. 13, 2016 (57 pages).
[cited by applicant]
ClinicalTrial.gov ID No. NCT02704429, “A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris”, last update posted Feb. 13, 2023 (49 pages).
[cited by applicant]
ClinicalTrial.gov ID No. NCT03395210, “A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)”, last update posted Jul. 28, 2023 (18 pages).
[cited by applicant]
ClinicalTrial.gov ID No. NCT03762265, “A Study of PRN1008 in Patients With Pemphigus”, last update posted Aug. 2, 2023 (104 pages).
[cited by applicant]
ClinicalTrial.gov ID No. NCT04520451, “Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Patients”, last update posted Sep. 7, 2023 (20 pages).
[cited by applicant]
ClinicalTrial.gov ID No. NCT04562766, “Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) (LUNA 3)”, last update posted Aug. 21, 2023 (24 pages).
[cited by applicant]
ClinicalTrial.gov ID No. NCT04748926, “Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy Participants”, last update posted Apr. 25, 2022 (20 pages).
[cited by applicant]
ClinicalTrial.gov ID No. NCT05002777, “Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)”, last update posted Jul. 27, 2023 (20 pages).
[cited by applicant]
ClinicalTrial.gov ID No. NCT05018806, “Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to- severe Atopic Dermatitis”, last update posted Jul. 6, 2023 (23 pages).
[cited by applicant]
ClinicalTrial.gov ID No. NCT05104892, “Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe Asthma”, last update posted Aug. 21, 2023 (25 pages).
[cited by applicant]
ClinicalTrial.gov ID No. NCT05107115, “Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine (RILECSU)”, last update posted Aug. 24, 2023…
[cited by applicant]
Cohen, M., et al., “Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors,” Science, 308:1318-1321 (2005).
[cited by applicant]
Cuker, A., et al., “How I treat refractory immune thrombocytopenia,” Blood, vol. 128, No. 12, pp. 1547-1554, Sep. 22, 2016.
[cited by applicant]
Database Biosis [Online], Biosciences Information Service, Kuter, D., et al., “Cognitive Impairment Among Patients with Chronic Immune Thromocytopenia,” Blood, vol. 140, suppl. 1, pp. 8422-8424 (2022).
[cited by applicant]
Database Biosis [Online], Biosciences Information Service, Langrish, C., et al., “PRN1008, a Reversible Covalent BTK Inhibitor in Cinical Development for Immune Thrombocytopenia Purpura,” Blood, vol. 130, suppl. 1, p. 1…
[cited by applicant]
Database Embase [Online], Elsevier Science Publishers, Kuter, D., “Oral Rilzabrutinib, a Bruton Tyrosine Kinase Inhibitor, Showed Clinically Active and Durable Platelet Responses and Was Well-Tolerated in Patients with …
[cited by applicant]
Database Embase [Online], Elsevier Science Publishers, Kuter, D., “Updated main study period and long-term extension (LTE) results with oral Bruton tyrosine kinase inhibitor rilzabrutinib in immune thrombocytopenia (ITP…
[cited by applicant]
Deng, Y., et al., “Reversible phospho-Smad3 signalling between tumour suppression and fibrocarcinogenesis in chronic hepatitis B infection,” Clin. Exp. Immunol., 176:102-111 (2013).
[cited by applicant]
Dias, A., et al., “Ibrutinib: A New Frontier in the Treatment of Chronic Lymphocytic Leukemia by Bruton's Tyrosine Kinase Inhibition,” Cardiovasc Hematol Agents Med Chem, 11 (4):265-271 (2013).
[cited by applicant]
Dick, et al., “Pemphigus: A treatment update,” Autoimmunity 2009, vol. 39, No. 7, pp. 591-599 (Jul. 7, 2009).
[cited by applicant]
Donald, A., et al., “Rapid Evolution of 6-Phenylpurine Inhibitors of Protein Kinase B through Structure-Based Design,” J Med. Chem., 50:2289-2292 (2007).
[cited by applicant]
Elinson, M., et al., “Electrochemical transformation of cyanoacetic ester and alkylidenecyanoacetic esters into 3-substituted 1,2-dicyanocyclopropane-1,2-dicarboxylates,” Russian Chemical Bulletin, 47(6):1133-1136 (1998…
[cited by applicant]
Elliott, M., et al., “Insecticidal activity of the Pyrethrins and Related Compounds x. ⋅ 5-Benzyl-3-furylmethyl 2,2-dimethylcyclopropanecarboxylates with ethylenic substituents at position 3 on the cyclopropane ring,” P…
[cited by applicant]
Elliott, M., et al., “The Pyrethrins and Related Compounds. Part XVIII. Insecticidal 2,2-Dimethylcyclopropanecarboxylates with New Unsaturated 3-Substituents,” Journal of the Chemical Society, Perkin Transactions 1: Org…
[cited by applicant]
English Language Abstract for JP 42008308 B4, published Apr. 8, 1967, by Yoshitomi Pharmaceutical Industries, Ltd. (1 page).
[cited by applicant]
English Translation of Office Action issued Apr. 12, 2013, in Chinese Application No. 201080061570.1.
[cited by applicant]
Hill, Q.A., et al., “The diagnosis and management of primary autoimmune haemolytic anaemia,” British Journal of Haematology, vol. 176, No. 3, pp. 395-411 (2017).
[cited by applicant]
Hodgson, K., et al., “Autoimmune cytopenia in chronic lymphocytic leukemia: diagnosis and treatment,” British Journal of Haematology, vol. 154, No. 1, pp. 14-22 (2011).
[cited by applicant]
Honigberg, L.A., et al., “The Bruton tyrosine kinase inhibitor PCT-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy,” PNAS, vol. 107, pp. 13075-13080 (2010).
[cited by applicant]
Horvath, B., et al., “Low dose rituximab is effective in pemphigus,” British Journal of Dermatology, vol. 166, No. 2, pp. 405-412 (2012).
[cited by applicant]
Hu, Chongmao, “Production and Application of a Pharmaceutical Excipient—Thin Film Coating,” Beijing: China Medical Science Press, p. 14 (May 31, 2014).
[cited by applicant]
Hu, Rongfeng, “Industrial Pharmaceutics,” Beijing: China Press of Traditional Chinese Medicine, pp. 237-239 (Jul. 31, 2010).
[cited by applicant]
Hutcheson, J., et al., “Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus,” Arthritis Research & Therapy, vol. 14, pp. R243 (2012).
[cited by applicant]
Ihrke, P.J., et al., “Pemphigus foliaceus in dogs: a review of 37 cases,” Journal of the American Veterinary Medical Association, vol. 186, No. 1, pp. 59-66 (1985).
[cited by applicant]
International Search Report for PCT/US2020/065689 mailed on Apr. 29, 2021 (9 pages).
[cited by applicant]
Irwin, S., “Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse,” Psychopharmacologia, vol. 13, No. 3, pp. 222-257 (1968).
[cited by applicant]
Ito, M., et al., “Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury,” Nature Communications, vol. 6, No. 1, p. 1 (2015).
[cited by applicant]
Ivankovic, S., Fehlende teratogene Wirkung von Nitroprussidnatrium (NNP) an Wistar-Ratten und Kaninchen [Absence of a teratogenic effect of sodium nitroprusside in wistar rats and rabbits (author's transl)]. Arzneimitte…
[cited by applicant]
Jager, U., et al., “Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting,” Blood Review, vol. 41, p. 100648 (2020).
[cited by applicant]
Joly, P., et al., “First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial,” Lan…
[cited by applicant]
Joly, P., et al., “Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis),” Clinical Dermatology, vol. 29, No. 4, pp. 432-436 (2011).
[cited by applicant]
Kamaly, Nazila, et al., “Degradable Controlled-Release Polymers and Polymeric Nanparticles: Mechanisms of Controlling Drug Release,” Chemical Reviews, vol. 116, pp. 2602-2663 (Feb. 8, 2016).
[cited by applicant]
Karra, E., et al., “The role of peptide YY in appetite regulation and obesity,” Journal of Physiology, vol. 587, No. 1, pp. 19-25 (2009).
[cited by applicant]
Khellaf, M., et al., “Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients,” Blood, vol. 124, No. 22, pp. 3228-3236 (2014).
[cited by applicant]
Kihlman, B.A., “Experimentally Induced Chromosome Aberrations in Plants, I. The production of chromosome aberrations by cyanide and other heavy metal complexing agents,” Journal of Biophysical & Biochemical Cytology, vo…
[cited by applicant]
Kim, K.H., et al., “Imidazo[1.5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis,” Bioorganic & Medicinal Chemical Letters, vol. 21, pp. 6258-6263 (2011).
[cited by applicant]
Klein, N.P., et al., “Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies,” Vaccine, vol. 28, No. 4, pp. 1062-1068 (2010).
[cited by applicant]
Kohrt, H.E., et al., “Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity,” Blood, vol. 123, No. 12, pp. 1957-1960 (2014).
[cited by applicant]
Kridin, K., et al., “Mortality and Cause of Death in Patients with Pemphigus,” Acta Dermato-Venereologica, vol. 97, No. 5, pp. 607-611 (2017).
[cited by applicant]
Kuter, D.J., et al., “22 oral rilzabrutinib Bruton tyrosine kinase inhibitor, showed clinically active and durable platelet responses and was well-tolerated in patients with heavily pretreated immune thrombocytopenia,” …
[cited by applicant]
Kuter, D.J., et al., “Phase I/II, open-label, adaptive study of oral tyrosine inhibitor patients with relapsed/refractory primary or secondary immune thrombodytopenia,” Blood, vol. 134 (Suppl 1), p. 87 (2019).
[cited by applicant]
Kuter, D.J., et al., “Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia,” MEJM Paper, vol. 386, No. 15, pp. 1421-1431 (2022).
[cited by applicant]
Kuter, D.J., et al., “Safety and efficacy of rilzabrutinib (PRN1008), an oral Bruton tyrosine kinase inhibitor, in relapsed/refractory patients with primary or secondary immune thrombocytopenia: Phase I/II adaptive stud…
[cited by applicant]
Langrish, C., et al., Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease, Journal of Immunology, vol. 206, No. 7, pp. 1454-1…
[cited by applicant]
Lindberg, H.A., et al., “Observations of the Pathologic Effects of Thiocyanate: An Experimental Study,” American Heart Journal, vol. 21, No. 5, pp. 605-616 (1941).
[cited by applicant]
Lipsky, A., et al., Managing toxicities of Bruton tyrosine kinase inhibitors, Hematology, American Society of Hematology Education Program, vol. 2020, No. 1, pp. 336-345 (2020).
[cited by applicant]
Mahoney, M.G., et al., “Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris,” Journal of Clinical Investigation, vol. 103, No. 4, pp. 461-468 (1999).
[cited by applicant]
Maronpot, R.R., et al., “Hepatic Enzyme Induction: Histopathology,” Toxicologic Pathology, vol. 38, pp. 776-795 (2010).
[cited by applicant]
Martin, Y.C., et al., “Do structurally similar molecules have similar biological activity?,” Journal of Medicinal Chemistry, vol. 45, No. 19, pp. 4350-4538 (2002).
[cited by applicant]
Masters, S.L., et al., “Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1Beta in type 2 diabetes,” Nature Immunology, vol. 11, No. 10, pp. 897-904 (2010).
[cited by applicant]
McKenzie, C.G., et al., “Cellular immune dysfunction in immune thrombocytopenia,” British Journal of Haematology, vol. 163, pp. 10-23 (2013).
[cited by applicant]
Metz, M., et al., “Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial,” Nature Medicine, vol. 27, No. 11, pp. 1961-1969 (2021).
[cited by applicant]
Michel, M., “Classification and therepeutic approaches in autoimmune hemolytic anemia: an update,” Expert Review of Hematology, vol. 4, No. 6, pp. 607-618 (2011).
[cited by applicant]
Michel, M., et al., “A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study),” American Journal of Hematology, vol…
[cited by applicant]
Mohamed, A.J., et al., Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain, Immunology Review, vol. 228, pp. 58-73 (2009).
[cited by applicant]
Montillo, M., et al., “Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the Resonate study,” Blood Cancer Journal 7, No. e524 Letter to the Editor (2017).
[cited by applicant]
Mosher, K.I., et al., “Go with your gut: microbiota meet microglia,” Nature Neuroscience, vol. 18, pp. 930-931 (2015).
[cited by applicant]
Murrell, D.F., et al., “Diagnosis and Management of Pemphigus: recommendations by an International Panel of Experts,” Journal of American Academy of Dermatology (2018).
[cited by applicant]
Nagasawa, H., et al., “Inhibitory effects of potassium thiocyanate on normal and neoplastic mammary development in female mice,” European Journal of Cancer, vol. 16, No. 4, pp. 473-480 (1980).
[cited by applicant]
Newman, K., et al., “Management of immune cytopenias in patients with systemic lupus erythematosus,” Autoimmunity Reviews, vol. 12, No. 7, pp. 784-791 (2013).
[cited by applicant]
Neys, S., et al., “Targeting Bruton's Tyrosine Kinase in Inflammatory and Autoimmune Pathologies,” Frontiers in Cell & Developmental Biology, vol. 9, p. 668131 (2021).
[cited by applicant]
Palmer, R.S., et al., “Clinical use of Potassium Sulfocyanate in Hypertension: A Preliminary Report of 59 Cases,” New England Journal of Medicine, vol. 201, No. 15, pp. 709-714 (1929).
[cited by applicant]
Peng, Tingting, et al., “Data on the drug release profiles and powder characteristics of the ethyl cellulose based microparticles prepared by the ultra-fine particle processing system,” Data in Brief, vol. 29, pages, No…
[cited by applicant]
Porro, A.M., et al., “Pemphigus vulgaris,” Anais Brasileiros de Dermatologia, vol. 94, No. 3, pp. 264-278 (2019).
[cited by applicant]
Press Release, “Sanofi to acquire Principia Biopharma,” Aug. 17, 2020.
[cited by applicant]
Rankin, A.L., et al., “Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis,” Journal of Immunology, vol. 191, No. 9, pp. 4540-4550 (2012).
[cited by applicant]
Kamath, S., et al., “Receptor-Guided Alignment-Based Comparative 3D-QSAR Studies of Benzylidene Malonitrile Tyrphostins as EGFR and HER-2 Kinase Inhibitors,” J Med. Chem., 46:4657-4668 (2003).
[cited by applicant]
Kamijo, S., et al., “Tetrazole synthesis via the palladium-catalyzed three component coupling reaction,” MolecularDiversity, 6: 181-192 (2003).
[cited by applicant]
Kamisawa, T., et al., “IgG4-related disease”, The Lancet, vol. 385, No. 9976, pp. 1460-1471 (2015).
[cited by applicant]
Kanwar, A., et al., “Rituximab in Pemphigus,” Indian J Dermatol. Venereal. Leprol. [serial online], 78:671-676 (2012).
[cited by applicant]
Kholodov, et al., “Clinical Pharmacokinetics,” Medicine, pp. 83-98, 134-138, 160, 378-380 (1985).
[cited by applicant]
Khosroshani, A., et al., “Rituximab for the treatment of IgG4-Related Disease,” Medicine, vol. 91, pp. 57-66 (2012).
[cited by applicant]
Knight, Z., et al., “A membrane capture assay for lipid kinase activity,” Nat Protoc., 2(10):2459-2466 (2017).
[cited by applicant]
Kojima, S., et al. “Stereoselective synthesis of activated cyclopropanes with an alpha-pyridinium acetamide bearing an 8-phenylmethyl group as the chiral auxiliary,” Tetrahedron Lett., 45(18): 3565-3568 (2004).
[cited by applicant]
Komura, K., et al., “Layered silicate PLS-1: A new solid base catalyst for C-C bond forming reactions,” Catal Commun., 8(4): 644-648 (2007).
[cited by applicant]
Kotz, A., et al., “The Action of Chloroform on Methylene and Metheny! Groups,” Journal fuer Praktische Chemie (Leipzig), Abstract, 74: 425-48 (1907).
[cited by applicant]
Kuter, D., et al., “LUNA3 Phase III Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of the Oral BTK Inhibitor Rilzabrutinib in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia,” …
[cited by applicant]
Kuter, D., et al., “Rilzabrutinib versus placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA3 phase III study,” Therapeutic Advances in Hematology, vol. 14, pp. 1-14 (2023).
[cited by applicant]
Langrish, C., et al., “PRN1008, a Reversible Covalent BTK Inhibitor in Clinical Development for Immune Thrombocytopenia Purpura,” Blood, vol. 130, suppl. 1, No. 1052 (2017).
[cited by applicant]
Leopold, C., “A Practical Approach in the Design of Colon-specific Drug Delivery System,” Wiley-VCH; Drug Targeting Organ-Specific Strategies, Chapter 6, pp. 157-170 (2001).
[cited by applicant]
Liang, C., et al., “The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review,” European Journal of Medicinal Chemistry, vol. 151, pp. 315-326 (2018).
[cited by applicant]
Liu, J., et al., “Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development”, European Journal of Medicinal Chemistry, vol. 217, Mar. 12, 2021, p. 113329.
[cited by applicant]
Lou, Y., et al., “Bruton's Tyrosine Kinase Inhibitors: Approaches to Potent and Selective Inhibition, Preclinical and Clinical Evaluation for Inflammatory Diseases and B Cell Malignancies,” J Med. Chem., 55(10): 4539-45…
[cited by applicant]
Maas, S., et al., “Conjugate Addition of Dialkylaluminum Chlorides to Alkylidenemalonic Acid Derivatives,” Synthesis, vol. 10, pp. 1792-1798 (1999).
[cited by applicant]
Mahajan, V., et al., “IgG4-Related Disease,” Annual Review of Pathology: Mechanisms of Disease, vol. 9, pp. 315-347 (2014).
[cited by applicant]
Maurya, R., et al., “Catalyst-free stereoselective cyclopropanation of electron deficient alkenes with ethyl diazoacetate,” RSC Advances, vol. 3, pp. 15600-15603 (2013).
[cited by applicant]
MedicineNet.com. Definition of Cancer. Web: (2004).
[cited by applicant]
MedlinePlus. Autoimmune Diseases, Web: (2014).
[cited by applicant]
Meydan, N., et al., “Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor,” Nature, vol. 379, pp. 645-648 (1996).
[cited by applicant]
Miller, R., “Electrophilic Fragment-Based Design of Reversible Covalent Kinase Inhibitors,” Journal of the American Chemical Society, vol. 135, No. 14, pp. 5298-5301 (2013).
[cited by applicant]
Murrell, D., et al., “A Pilot Study of the Efficacy of a Bruton's Tyrosine Kinase Inhibitor in the Treatment of Dogs with Pemphigus Foliaceus”, Australasian Journal of Dermatology, vol. 58, No. S1, p. 73 (Jan. 1, 2017).
[cited by applicant]
Nakamura, M. et al., “Diquafosol Ophthalmic Solution for Dry Eye Treatment,” Advances in Therapy, vol. 29, No. 7, pp. 579-589 (2012).
[cited by applicant]
Outerbridge, C., et al., “A new treatment for autoimmune blistering diseases—the efficacy of the Bruton's tyrosine kinase inhibitor PRN473 in canine pemphigus foliaceus,” Journal of American Academy of Dermatology, No. …
[cited by applicant]
Pan, Z. et al., “Discovery of Selective Irreversible Inhibitors for Bruton's Tyrosine Kinase,” ChemMedChem, vol. 2, pp. 58-61 (2007).
[cited by applicant]
Patani, G., et al., “Bioisosterism: A Rational Approach in Drug Design,” Chemical Reviews, vol. 96, pp. 3147-3176 (1996).
[cited by applicant]
Pennington, L., et al., “The Necessary Nitrogen Atom: A Versatile High-Impact Design Element for Multiparameter Optimization,” Journal of Medicinal Chemistry, vol. 60, No. 9, pp. 3552-3579 (2017).
[cited by applicant]
Porter, D., et al., “The discovery of potent, orally bioavailable pyrimidine-5-carbonitrile-6-alkyl CXCR2 receptor antagonists,” Bioorganic and Medicinal Chemistry Letters, vol. 24, pp. 3285-3290 (2014).
[cited by applicant]
Principia Biopharma: “A Study of PRN1008 in Adult Patients with Pemphigus Vulgaris”, ClinicalTrials.gov, (Mar. 10, 2016).
[cited by applicant]
Proenca, F., et al., “A simple and eco-friendly approach for the synthesis of 2-imino and 2-oxo-2H-chromene-3-carboxamides, ”Green Chemistry, vol. 10, pp. 995-998 (2008).
[cited by applicant]
Rellos, P., et al., “Structure and Regulation of the Human Nek2 Centrosomal Kinase,” Journal of Biological Chemistry, vol. 282, No. 9, pp. 6833-6842 (2007).
[cited by applicant]
Robak, T., et al., “Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders,” Expert Opinion on Investigational Drugs, vol. 21, No. 7, pp. 921-947 (2012).
[cited by applicant]
Rodeghiero, F., “A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP,” British Journal of Haematology, vol. 181, No. 2, pp. 183-195 (2018).
[cited by applicant]
Sammes, M., et al., “α-Cyano-sulphonyl Chlorides: Their Preparation and Reactions with Amines, Alcohols, and Enamines,” Journal of the Chemical Society, pp. 2151-2155 (1971).
[cited by applicant]
Sanofi Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia, Apr. 23, 2024.
[cited by applicant]
Santilli, A., et al., “8,9,10,11-Tetrahydro-12H-benzo[5,6]quinoxalino[2,3-e][1,4]diazepin-12-ones. Examples of a New Heterocyclic Ring System,” Journal of Organic Chemistry, vol. 29, pp. 2066-2068 (1964).
[cited by applicant]
Santus, G., et al., “Osmotic Drug Delivery: A Review of the Patent Literature,” Journal of Controlled Release, vol. 35, pp. 1-21 (1995).
[cited by applicant]
Schwarz, J., et al., “Novel Cyclopropyl β-Amino Acid Analogues of Pregabalin and Gabapentin That Target the α2-δ Protein,” Journal of Medicinal Chemistry, vol. 48, pp. 3026-3035 (2005).
[cited by applicant]
Schwobel, J., et al., “Prediction of Michael-Type Acceptor Reactivity toward Glutathione,” Chemical Research in Toxicology, vol. 23, pp. 1576-1585 (2010).
[cited by applicant]
Smith, P., et al., “A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers: A phase I study of PRN1008”, British Journal of Clinical Pharmacology, vol. 83, N…
[cited by applicant]
Stahl, P., et al., (Eds.) Handbook of Pharmaceutical Salts: Properties, Selection, and Use, Wiley-VCH; pp. 1-374 (2002).
[cited by applicant]
Stevens, C., et al., “Synthesis of Substituted Cyclopropylphosphonates by Michael Induced Ring Closure (MIRC) Reactions,” Synlett, vol. 7, pp. 1089-1092 (2002).
[cited by applicant]
Stone, J., et al., “Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations,” Arthritis Rheumatology, vol. 64, No. 10, pp. 3061-3067 (2012).
[cited by applicant]
Structure-Based Search Results (May 10, 2011, 10:04 AM), SciFinder.
[cited by applicant]
Structure-Based Search Results (May 10, 2011, 10:20 AM), SciFinder.
[cited by applicant]
Structure-Based Search Results (May 10, 2011, 10:46 AM), SciFinder.
[cited by applicant]
Structure-Based Search Results (May 9, 2011, 8:13 PM), SciFinder.
[cited by applicant]
Rip, J., et al., “The role of Bruton's tyrosine kinase in immune cell signaling and systemic autoimmunity,” Critical Reviews in Immunology, vol. 38, No. 1, pp. 17-62 (2018).
[cited by applicant]
Rogers, K.A., et al., “Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia,” Leukemia, vol. 30, pp. 346-350 (2016).
[cited by applicant]
Roumier, M., et al., “Characteristics and outcome of warm autoimmune hemolytic anemia in adults: New insights based on a single-center experience with 60 patients,” American Journal of Hematology, vol. 89, No. 9, pages …
[cited by applicant]
Sadeghi, Fatemeh, et al., “The influence of drug type of the release profiles from Surelease-coated pellets,” International Journal of Pharmaceuticals, vol. 254, pp. 123-135 (2003).
[cited by applicant]
Saloojee, Y., et al., “Carboxyhaemoglobin and plasma thiocyanate: complementary indicators of smoking behaviour,” Thorax, vol. 37, No. 7, pp. 521-525 (1982).
[cited by applicant]
Schwab, I., et al., “Intravenous immunoglobulin therapy: how does IgG modulate the immune system?,” Nature Reviews Immunology, vol. 13, pp. 176-189 (2013).
[cited by applicant]
Serafimova, I.M., et al., “Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles,” Nature Chemical Biology, vol. 8, No. 5, pp. 471-476 (2012).
[cited by applicant]
Cited By (1)